Latch Medical develops Pharma Latch, an intradermal drug delivery platform. The hollow, microneedle-based intradermal drug delivery technology is designed to enable precise, reliable and repeatable delivery of injectable therapies into the skin. The company developed it to support administration across a range of liquid formulations and drug volumes. It works across both clinical and at-home settings.
Dublin, Ireland-based Trinity Biotech said the collaboration aims to combine data streams from its CGM+ wearable biosensor platform with Latch Medical’s advanced drug delivery technologies. They hope to evaluate the development of precision therapeutic solutions for diabetes, obesity and other metabolic conditions.
Trinity’s AI-native CGM combines multi-sensor data with real-time analytics to meet the evolving demands of AI-powered healthcare and wellness. It could offer a fingerstick-free, calibration-free CGM option amid a competitive market. The company unveiled the CGM+ sensor in July 2025. Earlier this year, it said it intends to initiate a pivotal trial later this year, with regulatory submissions expected thereafter.
The companies intend to explore how real-time metabolic data from CGM+ can help guide and optimize precise therapy. They hope to enable more personalized, responsive treatment approaches.
As part of their collaboration, Trinity Biotech agreed in principle to make a strategic equity investment in Latch Medical.
Commentary from Trinity Biotech and Latch Medical officials
John Gillard, CEO of Trinity Biotech, said:
“We believe the future of metabolic healthcare lies at the intersection of advanced biosensing, artificial intelligence and precision drug delivery. Our vision for CGM+ extends beyond monitoring alone. We see the opportunity to create a platform capable of generating actionable metabolic intelligence that can help guide therapeutic interventions and improve patient outcomes.
“By combining our AI-native CGM+ platform with Latch Medical’s innovative precision drug delivery technology, we have an exciting opportunity to explore a new generation of metabolic health solutions. Our strategic collaboration and investment reflect our conviction that integrating advanced biosensing, AI and precision drug delivery has the potential to enable more personalised and responsive therapeutic interventions.”
Ronan Byrne, CEO of Latch Medical, said:
“Trinity Biotech’s vision for advanced metabolic monitoring creates an exciting opportunity to explore how biosensing and precision drug delivery technologies can work together. We are delighted to welcome Trinity Biotech as both a strategic collaborator and shareholder.”
